RNA干扰的治疗潜力。 - Suppr

Suppr

超能文献

Therapeutic potential of RNA interference.

作者信息

Stevenson Mario

机构信息

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.

出版信息

N Engl J Med. 2004 Oct 21;351(17):1772-7. doi: 10.1056/NEJMra045004.

DOI:10.1056/NEJMra045004

PMID:15496626

Abstract

摘要

相似文献

Therapeutic potential of RNA interference.

N Engl J Med. 2004 Oct 21;351(17):1772-7. doi: 10.1056/NEJMra045004.

RNA interference--small RNAs effectively fight viral hepatitis.

Liver Int. 2004 Dec;24(6):526-31. doi: 10.1111/j.1478-3231.2004.0960.x.

[RNA interference: biology and perspectives of application in biomedicine and biotechnology].

Mol Biol (Mosk). 2006 May-Jun;40(3):387-403.

MicroRNAs in common diseases and potential therapeutic applications.

Clin Exp Pharmacol Physiol. 2010 Jan;37(1):102-7. doi: 10.1111/j.1440-1681.2009.05269.x. Epub 2009 Aug 4.

[RNA interference: mechanism and applications].

Mikrobiyol Bul. 2004 Jul;38(3):285-94.

The silent treatment: RNAi as a defense against virus infection in mammals.

Trends Biotechnol. 2006 Apr;24(4):186-93. doi: 10.1016/j.tibtech.2006.02.006. Epub 2006 Feb 28.

The potential of RNA interference as a tool in the management of viral hepatitis.

J Hepatol. 2005 Jan;42(1):139-44. doi: 10.1016/j.jhep.2004.10.022.

RNA interference and potential therapeutic applications of short interfering RNAs.

Cancer Gene Ther. 2005 Oct;12(10):787-95. doi: 10.1038/sj.cgt.7700857.

Review article: RNA interference--potential therapeutic applications for the gastroenterologist.

Aliment Pharmacol Ther. 2008 May;27(9):715-23. doi: 10.1111/j.1365-2036.2008.03634.x. Epub 2008 Feb 1.

RNA interference: a potential revolution in disease therapy.

J Coll Physicians Surg Pak. 2006 Jul;16(7):491-2.

引用本文的文献

Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.

Noncoding RNA. 2023 Mar 22;9(2):21. doi: 10.3390/ncrna9020021.

A supramolecular platform for controlling and optimizing molecular architectures of siRNA targeted delivery vehicles.

Sci Adv. 2020 Jul 29;6(31):eabc2148. doi: 10.1126/sciadv.abc2148. eCollection 2020 Jul.

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.

Oncogene. 2016 Aug 25;35(34):4437-46. doi: 10.1038/onc.2015.514. Epub 2016 Feb 8.

Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.

Oncotarget. 2016 Jan 26;7(4):3984-92. doi: 10.18632/oncotarget.6766.

Time depended Bcl-2 inhibition might be useful for a targeted drug therapy.

Cancer Cell Int. 2015 Nov 2;15:105. doi: 10.1186/s12935-015-0254-5. eCollection 2015.

In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.

J Biomed Res. 2015 Apr;29(2):150-9. doi: 10.7555/JBR.29.20130024. Epub 2014 Dec 12.

Silencing of HIV-1 gag gene from epidemic strains among men who have sex with men (MSM) in Tianjin, China by a broad-spectrum short hairpin RNA.

Virusdisease. 2014;25(3):294-301. doi: 10.1007/s13337-014-0209-9. Epub 2014 Mar 29.

Study on the Biological Characteristics of CD133 (+) Cells Interfered by RNA Interference in Gastric Cancer.

ISRN Gastroenterol. 2014 Mar 19;2014:329519. doi: 10.1155/2014/329519. eCollection 2014.

Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.

PLoS One. 2014 May 2;9(5):e96623. doi: 10.1371/journal.pone.0096623. eCollection 2014.

Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.

Exp Ther Med. 2012 Feb;3(2):255-260. doi: 10.3892/etm.2011.381. Epub 2011 Nov 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Therapeutic potential of RNA interference.

作者信息

Stevenson Mario

机构信息

Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA.

出版信息

N Engl J Med. 2004 Oct 21;351(17):1772-7. doi: 10.1056/NEJMra045004.

DOI:10.1056/NEJMra045004

PMID:15496626

Abstract

摘要

相似文献

Therapeutic potential of RNA interference.

N Engl J Med. 2004 Oct 21;351(17):1772-7. doi: 10.1056/NEJMra045004.

RNA interference--small RNAs effectively fight viral hepatitis.

Liver Int. 2004 Dec;24(6):526-31. doi: 10.1111/j.1478-3231.2004.0960.x.

[RNA interference: biology and perspectives of application in biomedicine and biotechnology].

Mol Biol (Mosk). 2006 May-Jun;40(3):387-403.

MicroRNAs in common diseases and potential therapeutic applications.

Clin Exp Pharmacol Physiol. 2010 Jan;37(1):102-7. doi: 10.1111/j.1440-1681.2009.05269.x. Epub 2009 Aug 4.

[RNA interference: mechanism and applications].

Mikrobiyol Bul. 2004 Jul;38(3):285-94.

The silent treatment: RNAi as a defense against virus infection in mammals.

Trends Biotechnol. 2006 Apr;24(4):186-93. doi: 10.1016/j.tibtech.2006.02.006. Epub 2006 Feb 28.

The potential of RNA interference as a tool in the management of viral hepatitis.

J Hepatol. 2005 Jan;42(1):139-44. doi: 10.1016/j.jhep.2004.10.022.

RNA interference and potential therapeutic applications of short interfering RNAs.

Cancer Gene Ther. 2005 Oct;12(10):787-95. doi: 10.1038/sj.cgt.7700857.

Review article: RNA interference--potential therapeutic applications for the gastroenterologist.

Aliment Pharmacol Ther. 2008 May;27(9):715-23. doi: 10.1111/j.1365-2036.2008.03634.x. Epub 2008 Feb 1.

RNA interference: a potential revolution in disease therapy.

J Coll Physicians Surg Pak. 2006 Jul;16(7):491-2.

引用本文的文献

Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.

Noncoding RNA. 2023 Mar 22;9(2):21. doi: 10.3390/ncrna9020021.

A supramolecular platform for controlling and optimizing molecular architectures of siRNA targeted delivery vehicles.

Sci Adv. 2020 Jul 29;6(31):eabc2148. doi: 10.1126/sciadv.abc2148. eCollection 2020 Jul.

Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.

Oncogene. 2016 Aug 25;35(34):4437-46. doi: 10.1038/onc.2015.514. Epub 2016 Feb 8.

Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.

Oncotarget. 2016 Jan 26;7(4):3984-92. doi: 10.18632/oncotarget.6766.

Time depended Bcl-2 inhibition might be useful for a targeted drug therapy.

Cancer Cell Int. 2015 Nov 2;15:105. doi: 10.1186/s12935-015-0254-5. eCollection 2015.

In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.

J Biomed Res. 2015 Apr;29(2):150-9. doi: 10.7555/JBR.29.20130024. Epub 2014 Dec 12.

Silencing of HIV-1 gag gene from epidemic strains among men who have sex with men (MSM) in Tianjin, China by a broad-spectrum short hairpin RNA.

Virusdisease. 2014;25(3):294-301. doi: 10.1007/s13337-014-0209-9. Epub 2014 Mar 29.

Study on the Biological Characteristics of CD133 (+) Cells Interfered by RNA Interference in Gastric Cancer.

ISRN Gastroenterol. 2014 Mar 19;2014:329519. doi: 10.1155/2014/329519. eCollection 2014.

Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach.

PLoS One. 2014 May 2;9(5):e96623. doi: 10.1371/journal.pone.0096623. eCollection 2014.

Increase of the therapeutic effect on non-small-cell lung cancer cells with combination treatment of shRNA against Cyclin D1 and Bcl-xL in vitro.

Exp Ther Med. 2012 Feb;3(2):255-260. doi: 10.3892/etm.2011.381. Epub 2011 Nov 16.